PARVOVIRUS FOR TREATMENT OF TUMOURS BY INTRANASAL APPLICATION

摘要

Described is the use of an oncolytic parvovirus for the manufacture of a medicament for the treatment of a tumor and/or tumor metastases, in particular a brain tumor, by intranasal administration. A preferred parvovirus is H1-PV. Intranasal parvotherapy can improve the prognosis of said tumors. Parvovirus H1 infection leads to killing of tumor cells but does not harm normal brain cells. Thus, the intranasal use of a parvovirus like H1, a related virus or vectors based on such viruses offers the chance of tumor specific therapy without severe neurological side effects.